trending Market Intelligence /marketintelligence/en/news-insights/trending/4D6k1fo6vJeeKJUz8yF8ew2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Medica Clinical Nord Q3 profit climbs YOY

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID 19 Impact Recovery Media Telecom and Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Medica Clinical Nord Q3 profit climbs YOY

MedicaNatumin AB (publ) said its third-quarter normalized net income was 1.1 million kronor, an increase from 375,000 kronor in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin climbed to 5.2% from 1.6% in the year-earlier period.

Total revenue fell 12.3% on an annual basis to 20.6 million kronor from 23.5 million kronor, and total operating expenses fell 12.2% year over year to 20.2 million kronor from 23.0 million kronor.

Reported net income grew from the prior-year period to 1.6 million kronor, or 1 öre per share, from 200,000 kronor, or 0 öre per share.

As of Nov. 17, US$1 was equivalent to 8.75 Swedish kronor.